Brown A E, Quesada O, Armstrong D
Antimicrob Agents Chemother. 1982 Apr;21(4):592-4. doi: 10.1128/AAC.21.4.592.
Patients with cancer and suspected sepsis were treated in a prospective, randomized trial with one of four cephalosporin-aminoglycoside combinations: cephalothin and tobramycin; cephalothin and gentamicin; cefamandole and tobramycin; or cefamandole and gentamicin. Carbenicillin was added if the absolute granulocyte count was less than 1,000/mm3. Of 199 patients receiving 20 to more doses of an aminoglycoside and having serial determination of serum creatinines, nephrotoxicity developed in seven (3.5%) given any of the four combinations. There were no significant differences between patients receiving either cephalosporin or either aminoglycoside. Nephrotoxicity developed less frequently among children (2 or 125; 1.6%) than adults (5 of 74; 6.8%).
患有癌症且疑似败血症的患者参与了一项前瞻性随机试验，接受四种头孢菌素 - 氨基糖苷类组合之一的治疗：头孢噻吩和妥布霉素；头孢噻吩和庆大霉素；头孢孟多和妥布霉素；或头孢孟多和庆大霉素。如果绝对粒细胞计数低于1000/mm³，则添加羧苄西林。在199例接受20剂及以上氨基糖苷类药物并连续测定血清肌酐的患者中，接受四种组合中任何一种治疗的患者有7例（3.5%）发生了肾毒性。接受任何一种头孢菌素或任何一种氨基糖苷类药物的患者之间没有显著差异。儿童（2/125；1.6%）发生肾毒性的频率低于成人（74例中的5例；6.8%）。
